KN026
KN026 (anbenitamab) NDA Accepted by NMPA: First Domestic HER2 Bispecific in Gastric Cancer
China’s NMPA has accepted the NDA for Alphamab/CSPC’s KN026 (anbenitamab), the first domestic HER2 bispecific antibody to reach filing in gastric cancer. Backed by the KC-WISE Phase II/III trial, the drug could address a major gap in second-line HER2-positive gastric/GEJ adenocarcinoma.